摘要
目前晚期肝细胞癌的标准药物治疗是索拉菲尼，但其临床效果是有限的，而且副作用较大。但除索拉菲尼以外，在所有完成的Ⅲ期临床对照研究中，没有药物在作为一线或二线用药时能明显提高生存率。最近一项Ⅱ期随机对照研究结果的亚组分析显示，一种选择性MET抑制剂ARQ197，在全身治疗失败或不耐受全身治疗的伴有MET扩增的晚期肝细胞癌患者中应用，能明显提高总生存率。在本文中，我们对所有目前正在进行及已经完成临床试验的MET抑制剂做一综述。旨在进一步了解MET抑制剂在肝癌中的应用情况，为晚期肝癌的药物治疗提供新的策略。
Abstract
For advanced hepatocellular carcinoma (HCC),sorafenib is the only standard treatment option, whose clinical benefit is not only modest,but also having significant side effects.Recently few drugs ,in phase Ⅲ randomized controlled trials,can provide any significant improvement of survival as the first-or second-line option. Recently, the subgroup analysis of a phaseⅡrandomized controlled trial, patients with MET-positive advanced HCC after the failure or intolerance of a prior systemic therapy were enrolled ,has shown that ARQ197 as a selective MET inhibitor can significantly improve the overall survival (OS).Writing the paper is to further understand the application of MET inhibitors in liver cancer and provide a new strategy for the treatment of advanced hepatocellular carcinoma. .
NETL
NSTL
维普
万方数据